Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023)

Table 1

Phase 1 dose escalation schema.

Dose level	Ganetespib (mg/m^2), intravenously on days 1, 8, and 15 of each 28-day cycle	Sirolimus (mg), oral		Number of evaluable patients
		Loading dose, cycle 1, day 1 only	Maintenance dose, orally once daily continuously
−2	100	6	2	–
−1	150	6	2	–
1	150	12	4	3
2	200	12	4	6

Starting dose: 1 cycle = 28 days.